

## **Minutes of the Institute Biosafety Committee Meeting**

**August 12, 2026**

**Convened at: 1:00 pm and Adjourned at 2:46 pm**

**Present:** Drs. Gelman (Chair), Ding, Fang, Gerber, Ionov, McGray, Thanavala, Ms. Holtz and Ms Keough.

**Absent:** Mr. Atwal, Mr. Hartley, Mr. Flagler, Ms. Pusateri

**ORSP Staff:** Ms. Herter, Mr. Caruana, Ms. Bennett

**Guests:** None

**Meeting Place:** Virtual meeting/Teams.

**Minutes** of July 15, 2026 were approved.

**Vote:** Unanimous.

### **Adverse Event/Accident/Incident Report**

Employee Health Service report; June and July report; no incidents.

ORSP - No reports.

### **Old Business**

1. Safety Story; this months story highlighted proper labeling of cages when cells or compounds are administered to mice.
2. Laboratory inspections; June and July pending.  
Laboratories were visited June 11th with Dr. Ionov and Ms Bennett joining the team.
  - a. Fenstermaker/Ciesielski BSL2lab: OES to follow up (see checklist).
  - b. Takabe/Hait BSL2 lab: OES to follow up (see checklist).
  - c. Knudsen BSL2+ lab: OES to follow up (see checklist).Laboratories were visited July 2nd with Dr McGray joining the team.
  - a. Bakin BSL2+ Lab: OES to follow up (see checklist).
  - b. Tang BSL2+ Lab: OES to follow up (see checklist).

### **New Business:**

1. Lab educational visits:  
There were no lab inspections performed in August.  
The next inspection date will be Thursday, September 10<sup>th</sup> with Dr. Ionov joining the team.
2. Dr Gerber informed of an inquiry made by a PI regarding the use of BSCs that are restricted for 2+ work only. After discussion, clarified that other work not designated as 2+ could be performed in that BSC but the personnel would need to follow all 2+ precautions.
3. Use of ultracentrifuge in tissue culture rooms. Dr. Gerber pointed out that a line in the 2+ SOP appears to allow for viral centrifugation in an open lab space. The SOP will be reviewed and clarified to state this work should only be done in an ultracentrifuge in a tissue culture room designated as 2+.
4. Incidents; the committee was informed of 2 recent incidents. First, a PI self reported the use of a human cell line in mice prior to receiving IACUC and IBC approval. The PI submitted amendments, which were ultimately approved for the work, in addition to a CAPA outlining steps put in place for this error to not occur again. The IACUC and the IBC found the CAPA acceptable.  
Second, COSR staff reported to the IBC, a PI that had administered tamoxifen to his mice and had not properly labeled the cages, potentially exposing animal care takers to the hazard. COSR staff contacted the PI staff upon discovery and cages were then properly labeled. After discussion, the IBC will send the PI a memo requesting details of what occurred and steps they will put in place to avoid this from happening in the future.

Protocol review:

19 Biosafety applications were reviewed. 7 were continuing reviews.

## **5 Protocols referenced Virus**

Application for 1489M/Lab Based: Approved pending.

Reviewed by Dr. Ding

The 1489M/lab based application, 26-05-1741 entitled: "An Oncogenic Role of Agrin in Liver and Lung Tumorigenesis" PI: Chakraborty, Sayan was approved pending designated member review of a revised application.

The purpose of this protocol is to analyze the role of agrin in NSCLC and HCC models.

Biosafety agents include: adenovirus, lentivirus, AAV9, and compounds.

Application for P 4947926: Approved pending.

Reviewed by Dr. McGray

The P 4947926 application, 26-05-1742 entitled: "A Phase 1/2, Open Label Study to Investigate the Safety and Efficacy of Membrane Bound IL 15 Expressing Tumor-Infiltrating Lymphocytes (OBX-115) in Participants with Advanced Solid Tumors." PI: Krishnamurthy, Anuradha was approved pending designated member review of a revised application.

The purpose of this protocol is to test the efficacy and safety of Membrane Bound IL 15 Expressing Tumor-Infiltrating Lymphocytes (OBX-115) in Participants with Advanced Solid Tumors.

Biosafety agents include: retrovirus

Application for I-3832925: Approved pending.

Reviewed by Dr. McGray

The I-3832925 application, 26-06-1751 entitled: "A Phase I Trial of Bispecific CD19/CD20-Targeted Chimeric Antigen Receptor (CAR) Modified T Cells with 4-1BB and Mutated CD28 Costimulatory Domains in Patients with Relapsed or Refractory CD19+ Hematologic Malignancies." PI: Niu, Alex was approved pending designated member review of a revised application.

The purpose of this protocol is to test the safety of a bispecific CD19/CD20-targeted chimeric antigen receptor (CAR) modified T cells with 4-1BB and mutated CD28 costimulatory domains in patients with relapsed or refractory CD19+ hematologic malignancies.

Biosafety agents include: retrovirus

Application for UB1245M/Lab Based: Approved pending.

Reviewed by Dr. Gelman

The amendment application for full committee review 25-01-1648 entitled: "Biosafety for Modulation of Glial Cell Development by Golli Myelin Proteins and Calcium Channels." PI: Paez, Pablo was approved pending designated member review of revised application.

The purpose of this protocol is to study the role of various genes in the myelination of nerves in a model of multiple sclerosis.

Biosafety agents include: AAV and compounds.

Application for 1612M/Lab Based: Approved pending.

Reviewed by Dr. Fang

The amendment application for full committee review 25-02-1652 entitled: "Ohm Lab Biosafety Protocol." PI: Ohm, Joyce was approved pending designated member review of revised application. The purpose of this protocol is to study the role of combination chemotherapies in models of Ewings sarcoma.

Biosafety agents include: lentivirus, retrovirus and compounds.

## **1 Application referenced Toxin:**

Application for 1727M/Lab Based: Approved pending.

Reviewed by Dr. Ionov

The amendment application for full committee review 25-08-1689 entitled: "Evaluation of the Safety and Efficacy of Novel Combination Therapies and Preventions of Oral and Head and Neck Cancers." PI: Seshadri, Mukund was approved pending designated member review of revised application.

The purpose of this protocol is to evaluate combination chemotherapies in models of head-and-neck cancers.

Biosafety agents include: Cholera Toxin and numerous compounds.

Exempt from full committee review:

Application for 1381M/Lab Based: Approved.

Reviewed by Dr. McGray

The application, 24-05-1597 entitled: "Regulation of GPCR Signaling in Cancer." PI: Feigin, Michael was approved as Exempt from full committee review 8/11/2026.

Biosafety agents include: CRISPR, cell lines and compounds.

## **Amendments:**

Application for 1461M/Lab Based: Approved.

Reviewed by Dr. Gelman

The amendment to 1461M/Lab based 25-07-1681 entitled: "Genetic Targeting of T Lymphocytes to Cancer Antigens for Use in Adoptive Cell Therapy" PI: Brentjens, Renier was approved on 7/27/2026.

Biosafety agents used include: new human cell line.

Application for 1749M/Lab Based: Approved.

Reviewed by Dr. Gelman

The amendment to 1749M/Lab based 25-11-1702 entitled: "McLean Laboratory" PI: McLean, Karen was approved 7/29/2026.

Biosafety agents used include: cell lines and compounds.

Application for Core Lab Based: Approved.

Reviewed by Dr. Gelman

The amendment to Lab based 23-12-1557 entitled: "Laboratory Animal Resources Research" PI: Curtin, Leslie was approved 7/29/2026.

Biosafety agents used include: compounds and cell lines.

Application for Lab based: Approved.

Reviewed by Dr. Thanavala

The amendment to Lab based 24-05-1600 entitled: "Gelman Lab Biosafety Application" PI: Gelman, Irwin was approved 7/30/2026.

Biosafety agents used include: Modified cells.

Application for 1094M/Lab based: Approved.

Reviewed by Dr. Gelman

The amendment to 1094M/Lab based 25-09-1691 entitled: "The Study of CAR-T Cells and Multiple Myeloma" PI: Olejniczak, Scott was approved 8/11/2026.

Biosafety agents used include: Modified cell line.

See attached for complete list.

Respectfully Submitted,

A handwritten signature in blue ink, reading "Irwin Gelman". The signature is fluid and cursive, with the first name "Irwin" and last name "Gelman" clearly distinguishable.

Irwin Gelman, PhD  
Institute Biosafety Committee Chair  
Director of Research Integration; Professor of  
Oncology